SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide
Rhea-AI Summary
Scienture (NASDAQ: SCNX) reported progress in commercializing Arbli, a losartan potassium oral suspension, through expanded payor coverage and pharmacy access.
The company added approximately 12.5 million incremental covered lives across commercial, Medicare Part D, and government channels, targeting higher prescription volume within the $219 million, 72 million‑prescription U.S. losartan market.
AI-generated analysis. Not financial advice.
Positive
- Approximately 12.5 million incremental covered lives added for Arbli
- Broader access through commercial, Medicare Part D, and government-sponsored plans
- Ongoing initiatives to increase Medicaid access for Arbli
- Expansion of pharmacy participation and buying group relationships
- Development of specialty technology and distribution channel partnerships
- Targeting a $219 million U.S. losartan market with about 72 million prescriptions annually
Negative
- None.
News Market Reaction – SCNX
On the day this news was published, SCNX gained 2.24%, reflecting a moderate positive market reaction. Argus tracked a peak move of +5.4% during that session. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $380K to the company's valuation, bringing the market cap to $17.34M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Peers on Argus
SCNX was up 1.52% ahead of this coverage update, while close peers showed mixed moves (notably SSY up and HKPD, HITI down), indicating a stock-specific rather than sector-wide driver.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jun 09 | Coverage expansion | Positive | +4.0% | Large national health plan added REZENOPY to formulary, expanding covered lives. |
| Jun 04 | Investor conference | Neutral | +0.0% | Management participation in Small Cap Showcase with webcast and investor meetings. |
| Jun 02 | Patent grant | Positive | -1.4% | New U.S. patent granted for REZENOPY nasal spray with protection to 2041. |
| May 18 | Earnings update | Negative | -2.3% | Q1 2026 results showed strong revenue growth but continued sizable net loss. |
| May 07 | Debt financing | Positive | +8.6% | Secured non-dilutive debt financing to fund commercialization and R&D pipeline. |
Recent news, especially on financing and market access, has usually produced modestly positive price reactions, with only one clear divergence on a strong patent update.
Regulatory & Risk Context
Reported short interest reflects relatively low short positioning, suggesting limited short-squeeze fuel but also a lower risk of forced covering volatility based on current data.
An active S-3 shelf registration allows the company to issue additional securities under an existing registration statement, which can provide financing flexibility but also raises ongoing dilution considerations for shareholders.
Market Pulse Summary
This announcement enhances Arbli’s reach by adding about 12.5 million covered lives within a $219 million losartan market. It builds on a pattern of commercial progress, though leverage and potential future equity issuance remain important risks to monitor.
Key Terms
medicare part d regulatory
medicaid regulatory
pharmacy compounding technical
oral suspension medical
AI-generated analysis. Not financial advice.
Broader pharmacy access, channel expansion, and payer coverage position Arbli™ for increased prescription volume and revenue growth
COMMACK, NY, June 18, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced significant progress in the commercialization of Arbli™ (losartan potassium oral suspension), including expanded payor coverage, broader pharmacy access, new channel partnerships, and ongoing initiatives designed to increase patient access across commercial, Medicare, and Medicaid markets.
The Company recently secured additional payor coverage representing approximately 12.5 million incremental covered lives, including expanded access through Medicare Part D supplement plans and other commercial and government-sponsored healthcare channels. These additions build upon Scienture's existing reimbursement footprint and further increase patient access to Arbli™ nationwide.
In addition to expanding coverage, Scienture is working to strengthen Arbli™'s commercial infrastructure by targeting the expansion of pharmacy participation, relationships with pharmacy buying groups, specialty technology participation, and distribution capabilities. The Company is also advancing initiatives that are expected to increase Medicaid access and expand Arbli™'s presence across additional healthcare channels.
“Expanding patient access remains one of our highest priorities as we continue to commercialize Arbli™,” commented Narasimhan Mani, President and co-CEO of Scienture. “The addition of approximately 12.5 million covered lives, coupled with our growing pharmacy network, specialty technology relationships, and channel partnerships, represents another important step in increasing awareness, availability, and utilization of Arbli™. We expect that these initiatives will strengthen our commercial infrastructure and position us to drive increased prescription volume across multiple healthcare channels.”
Arbli™ is a proprietary oral suspension formulation of losartan potassium designed to improve patient access and compliance, particularly among pediatric, geriatric, and other patient populations with difficulty swallowing tablets, within the approximately
“With approximately 72 million losartan prescriptions written annually in the United States and a market of
About Arbli™
Arbli™ is a novel proprietary formulation of losartan, a widely prescribed angiotensin receptor blocker (ARB) for hypertension. It is the first and only liquid formulation of losartan on the market that does not require compounding and has reduced dosing volume and long-term shelf life at room temperature storage. Arbli™ is FDA-approved for the treatment of hypertension in patients greater than six years old, for reducing the risk of stroke in patients with hypertension and left ventricular hypertrophy, and for treating diabetic nephropathy in certain patients with type 2 diabetes. By offering a safe, effective, and convenient liquid alternative, Arbli™ provides a tailored solution for patients who require or prefer a liquid formulation. As an FDA-approved product, Arbli™ provides consistent quality and dosing accuracy, addressing the risks and inconsistencies often associated with extemporaneously compounded losartan prescriptions. Arbli™ has two issued patents from the USPTO, which are also listed in the FDA Orangebook.
Arbli™ is the first and only oral liquid formulation of losartan approved by the U.S. FDA. Arbli™ comes in a 165 mL bottle as a peppermint flavored suspension that does not require refrigeration and has been approved for a shelf life of 24 months from the date of manufacture when stored at room temperature.
INDICATION
Arbli™ is an angiotensin II receptor blocker (ARB) indicated for:
- Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
- Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy.
- Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension.
IMPORTANT SAFETY INFORMATION
- Do not take Arbli™ when pregnant. When pregnancy is detected, discontinue Arbli™ as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. Arbli™ can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death.
- Do not co-administer Arbli™ with aliskiren in patients with diabetes. Avoid use of aliskiren with Arbli™ in patients with renal impairment (GFR <60 mL/min).
- Do not administer Arbli™ in patients with severe hepatic impairment. Arbli™ has not been studied in patients with severe hepatic impairment.
- The most common adverse reactions are (incidence ≥
2% and greater than placebo): dizziness, upper respiratory infection, nasal congestion, and back pain.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also contact Scienture at 1-833-754-4917.
Please see the full Prescribing Information for complete product information. For more information, talk to your healthcare provider.
About Hypertension
Hypertension (high blood pressure) is a cardiovascular condition, when the pressure in the blood vessels is too high (140/90 mmHg or higher). According to the CDC, hypertension, or high blood pressure, affects nearly half of adults in the United States, or approximately 119.9 million people. Hypertension is defined as a systolic blood pressure of 140 mmHg or higher, and diastolic blood pressure of 90 mmHg or higher. Hypertension is a risk factor for stroke and heart disease, which are leading causes of death in the U.S. Factors that increase the risk of having high blood pressure include: older age, genetics, being overweight or obese, not being physically active, high-salt diet and drinking too much alcohol. Hypertension is clinically diagnosed if, when blood pressure is measured on two different days, the systolic blood pressure readings on both days is ≥140 mmHg and/or the diastolic blood pressure readings on both days is ≥ 90 mmHg.
About Scienture Holdings, Inc.
SCIENTURE HOLDINGS, INC. (NASDAQ: “SCNX”), through its wholly owned subsidiary, Scienture, LLC, is a comprehensive pharmaceutical product company focused on providing enhanced value to patients, physicians and caregivers by offering novel specialty products to satisfy unmet market needs. Scienture, LLC is a branded, specialty pharmaceutical company consisting of a highly experienced team of industry professionals who are passionate about developing and bringing to market unique specialty products that provide enhanced value to patients and healthcare systems. The assets in development at Scienture are across therapeutics areas, indications and cater to different market segments and channels. For more information please visit: www.scientureholdings.com and www.scienture.com.
Cautionary Statements Regarding Forward-Looking Statements
This press release contains certain statements that may be deemed to be “forward-looking statements” within the federal securities laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry, our beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, including for the products we may launch, such as Arbli™, the success those products may have in the marketplace, and our strategies related to those products. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” or the negative of these terms or other similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are subject to a number of risks and uncertainties (some of which are beyond our control) that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. These risks include risks relating to agreements with third parties; our ability to raise funding in the future, as needed, and the terms of such funding, including potential dilution caused thereby; our ability to continue as a going concern; security interests under certain of our credit arrangements; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; claims relating to alleged violations of intellectual property rights of others; the outcome of any current legal proceedings or future legal proceedings that may be instituted against us; unanticipated difficulties or expenditures relating to our business plan; and those risks detailed in our most recent Annual Report on Form 10-K and subsequent reports filed with the SEC.
Forward-looking statements speak only as of the date they are made. Scienture Holdings, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided by law.
Contact:
SCIENTURE HOLDINGS, INC.
20 Austin Blvd
Commack, NY 11725
Phone: (866) 468-6535
Email: IR@Scienture.com
